Pharvaris N.V.

NASDAQ

Market Cap.

938.92M

Avg. Volume

69.58K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Pharvaris N.V.

Pharvaris N.V. News

Pharvaris N.V. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareBiotechnology
pharvaris.com

About Pharvaris N.V.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Pharvaris N.V. Earnings & Revenue

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

Pharvaris N.V. Financials

Table Compare

Compare PHVS metrics with:

   

Earnings & Growth

PHVS

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

PHVS

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

PHVS

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

PHVS

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Pharvaris N.V. Income

Pharvaris N.V. Balance Sheet

Pharvaris N.V. Cash Flow

Pharvaris N.V. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioBuy
Price/Earnings RatioStrong Sell
Price/Book RatioSell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Pharvaris N.V. Executives

NameRole
Mr. Berndt Axel Edvard Modig CPA, M.B.A.Co-Founder, Chief Executive Officer & Executive Director
Ms. Annick DeschoolmeesterChief Human Resources Officer
Dr. Peng Lu M.D., Ph.D.Chief Medical Officer
Mr. David W. Nassif J.D.Chief Financial Officer, Chief Legal Officer & Corporate Secretary
Dr. Anne A. Lesage Ph.D.Chief Early Development Officer
NameRoleGenderDate of BirthPay
Mr. Berndt Axel Edvard Modig CPA, M.B.A.Co-Founder, Chief Executive Officer & Executive DirectorMale1959649.77K
Ms. Annick DeschoolmeesterChief Human Resources OfficerFemale1973

--

Dr. Peng Lu M.D., Ph.D.Chief Medical Officer1978

--

Mr. David W. Nassif J.D.Chief Financial Officer, Chief Legal Officer & Corporate SecretaryMale1954

--

Dr. Anne A. Lesage Ph.D.Chief Early Development Officer1961

--

Discover More

Streamlined Academy

Pharvaris N.V.

NASDAQ

Market Cap.

938.92M

Avg. Volume

69.58K

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Pharvaris N.V. News

Pharvaris N.V. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

Pharvaris N.V. Earnings & Revenue

Pharvaris N.V. Income

Pharvaris N.V. Balance Sheet

Pharvaris N.V. Cash Flow

Pharvaris N.V. Financials Over Time

Pharvaris N.V. Executives

NameRole
Mr. Berndt Axel Edvard Modig CPA, M.B.A.Co-Founder, Chief Executive Officer & Executive Director
Ms. Annick DeschoolmeesterChief Human Resources Officer
Dr. Peng Lu M.D., Ph.D.Chief Medical Officer
Mr. David W. Nassif J.D.Chief Financial Officer, Chief Legal Officer & Corporate Secretary
Dr. Anne A. Lesage Ph.D.Chief Early Development Officer
NameRoleGenderDate of BirthPay
Mr. Berndt Axel Edvard Modig CPA, M.B.A.Co-Founder, Chief Executive Officer & Executive DirectorMale1959649.77K
Ms. Annick DeschoolmeesterChief Human Resources OfficerFemale1973

--

Dr. Peng Lu M.D., Ph.D.Chief Medical Officer1978

--

Mr. David W. Nassif J.D.Chief Financial Officer, Chief Legal Officer & Corporate SecretaryMale1954

--

Dr. Anne A. Lesage Ph.D.Chief Early Development Officer1961

--

Pharvaris N.V. Insider Trades

No data available

DateNameRoleTransactionTypeShares

No data available

Streamlined Academy

Website screenshot
HealthcareBiotechnology
pharvaris.com

About Pharvaris N.V.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Pharvaris N.V.

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

Pharvaris N.V. Financials

Table Compare

Compare PHVS metrics with:

   

Earnings & Growth

PHVS

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

PHVS

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

PHVS

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

PHVS

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioBuy
Price/Earnings RatioStrong Sell
Price/Book RatioSell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

The Secret to Analyzing Winning Stocks (Step-by-Step Examples Inside)